Food and Drug Administration (FDA) announced that dasatinib may increase the risk of a rare but serious condition in which there is abnormally high blood pressure in the arteries of the lungs ( pulmonary hypertension, PAH).

Several cases of pulmonary arterial hypertension (PAH) were found in people treated with dasatinib, possibly due to pulmonary endothelial cell damage. Mild hypocalcemia was also noted, but did not appear to cause any significant problems. A small number of people developed abnormal liver function tests which returned to normal without dose adjustments. Other adverse events included mild to moderate diarrhea, peripheral edema, and headache. Some of these people required thoracentesis or pleurodesis to treat the effusions.

18%) in the above-mentioned study developed pleural effusions, which was a suspected side effect of dasatinib. Neutropenia and myelosuppression were common toxic effects. The most common side effects are infection, suppression of the bone marrow (decreasing numbers of leukocytes, erythrocytes, and thrombocytes), headache, hemorrhage (bleeding), pleural effusion (fluid around the lungs), dyspnea (difficulty breathing), diarrhea, vomiting, nausea (feeling sick), abdominal pain (belly ache), skin rash, musculoskeletal pain, tiredness, swelling in the legs and arms and in the face, fever. Ph+ acute lymphoblastic leukaemia (ALL) and lymphoid blast CML with resistance or intolerance to prior therapy.

chronic, accelerated or blast phase CML with resistance or intolerance to prior therapy including imatinib mesilate.newly diagnosed Philadelphia-chromosome-positive (Ph+) chronic myelogenous leukaemia (CML) in the chronic phase.newly diagnosed Ph+ CML in chronic phase (Ph+ CML-CP) or Ph+ CML-CP resistant or intolerant to prior therapy including imatinib.newly diagnosed Ph+ acute lymphoblastic leukaemia (ALL) in combination with chemotherapy.newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukaemia in chronic phase (Ph+ CML CP) or Ph+ CML CP resistant or intolerant to prior therapy including imatinib.In the EU dasatinib is indicated for children with Dasatinib is used to treat people with chronic myeloid leukemia and people with acute lymphoblastic leukemia who are positive for the Philadelphia chromosome.

Teamviewer license price in india